Adamczyk Agnieszka, Niemiec Joanna, Ambicka Aleksandra, Małecki Krzysztof, Wysocki Wojciech H, Mituś Jerzy, Ryś Janusz
Department of Applied Radiobiology, Centre of Oncology-Maria Skłodowska-Curie, Memorial Institute, Krakow, Poland.
Pol J Pathol. 2012 Dec;63(4):228-34. doi: 10.5114/pjp.2012.32769.
The immunophenotypic differences between primary and metastatic tumour cells could influence patient's treatment or/and the results of selected diagnostic procedures. That prompted us to investigate potential differences between primary tumours and corresponding synchronous lymph node metastases in the T 1/N+/M0 breast cancer patients. The investigated group consisted of 108 patients with invasive ductal breast cancer, who underwent radical surgery. The expression of ER, PR, HER2 as well as CK5/6, P-cadherin, EGFR and Ep-CAM was assessed immunohistochemically. Our data suggest that ER, PR, HER2, EGFR and CK5/6 are expressed conservatively, with some minor changes between primary tumour and simultaneous lymph node metastases. On the contrary, Ep-CAM and P-cadherin immunoreactivity in primary and metastatic cells varied significantly. This variation might exclude Ep-CAM and P-cadherin as potential diagnostic or therapeutic targets.
原发性肿瘤细胞与转移性肿瘤细胞之间的免疫表型差异可能会影响患者的治疗或/和所选诊断程序的结果。这促使我们研究T≥1/N+/M0乳腺癌患者原发性肿瘤与相应同步淋巴结转移之间的潜在差异。研究组由108例行根治性手术的浸润性导管癌患者组成。采用免疫组织化学法评估ER、PR、HER2以及CK5/6、P-钙黏蛋白、EGFR和Ep-CAM的表达。我们的数据表明，ER、PR、HER2、EGFR和CK5/6表达保守，原发性肿瘤与同期淋巴结转移之间有一些微小变化。相反，原发性和转移性细胞中Ep-CAM和P-钙黏蛋白的免疫反应性差异显著。这种差异可能排除Ep-CAM和P-钙黏蛋白作为潜在的诊断或治疗靶点。
